Vaxcyte (PCVX) Current Assets (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Current Assets data on file, last reported at $1.8 billion in Q1 2026.

• On a quarterly basis, Current Assets rose 5.65% year-over-year to $1.8 billion in Q1 2026; TTM through Mar 2026 was $1.8 billion, a 5.65% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, down 8.98% from the prior year.
• Current Assets for Q1 2026 stood at $1.8 billion, up from $1.6 billion in the prior quarter.
• Over the last five years, Current Assets for PCVX reached as high as $2.2 billion in Q3 2024 and fell as low as $342.2 million in Q1 2022.
• Historically, Current Assets has averaged $1.3 billion across 5 years, with a median of $1.5 billion in 2024.
• Across the five-year window, Current Assets soared 267.69% in 2022 and retreated 20.18% in 2025, its largest moves.
• Year by year, Current Assets stood at $942.6 million in 2022, then advanced by 16.27% to $1.1 billion in 2023, then jumped by 63.14% to $1.8 billion in 2024, then fell by 8.98% to $1.6 billion in 2025, then climbed by 11.44% to $1.8 billion in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $1.8 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.8 billion in Q3 2025.